Jay Knowles

Jay Knowles joined Mass General Brigham Ventures in 2014 as a Partner. Previously, Jay was CEO of X-BODY Biosciences (acquired by Juno). Prior to X-BODY, he was at Novartis in charge of the Platforms team for Strategic Alliances, responsible for global technology and drug discovery collaborations. Jay was also President of Novalar, Vice President of Business Development at Novacea, and Director, R&D Planning at Vertex Pharmaceuticals. He earned his MBA in Finance from Wharton Business School, an M.Sc. in Chemistry from UC Berkeley, and a BA with Distinction in Chemistry from Carleton College. He represents Partners on the boards of Apres, Keros (KROS), ROME, Swan, and Triplet. Previous recent investments include Akouos (AKUS), Denali (DNLI), Editas (EDIT), Tilos (acquired by Merck), and Translate (TBIO).